FDA Approves Trastuzumab Biosimilar
On December 1, the FDA approved a second cancer biosimilar, trastuzumab-dkst. The drug was approved to treat patients with HER2-positive breast and metastatic stomach cancers.
Saved in:
| Published in | Cancer discovery Vol. 8; no. 2; p. 130 |
|---|---|
| Format | Journal Article |
| Language | English |
| Published |
United States
01.02.2018
|
| Online Access | Get full text |
Cover
Loading…
| Summary: | On December 1, the FDA approved a second cancer biosimilar, trastuzumab-dkst. The drug was approved to treat patients with HER2-positive breast and metastatic stomach cancers. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 2159-8274 2159-8290 |
| DOI: | 10.1158/2159-8290.CD-NB2017-183 |